APGE
Apogee Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.27B
P/E Ratio
—
EPS
$-4.22
Beta
1.02
52W High
$85.94
52W Low
$27.15
50-Day MA
$71.44
200-Day MA
$57.49
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-284.18M |
| Operating Margin | 0.00% |
| Return on Equity | -31.60% |
| Return on Assets | -21.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $13.21 |
| Price-to-Book | 6.96 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $61.11M |
| Float | $52.96M |
| % Insiders | 5.48% |
| % Institutions | 121.01% |
Analyst Ratings
Consensus ($116.87 target)
14
Buy3
HoldData last updated: 4/7/2026